Rep. Brennan Issues Statement on JCARR Review of Synthetic Kratom Rule

COLUMBUS – State Rep. Sean Patrick Brennan (D–Parma) today issued the following statement after the Joint Committee on Agency Rule Review (JCARR) considered a rule from the Ohio Board of Pharmacy addressing synthetic kratom compounds.

“As a member of JCARR, I supported allowing this rule to move forward,” said Rep. Brennan. “This rule takes an important and targeted approach to addressing serious public health concerns associated with synthetic kratom compounds.”

The rule classifies mitragynine-related compounds (aka kratom) that are synthetic as Schedule I controlled substances. It does not apply to kratom in its natural, vegetative form, such as kratom leaf or ground natural leaf. It also excludes any medication approved by the FDA. 

The Board of Pharmacy initially enacted a temporary ban on synthetic kratom through an executive order issued by Governor Mike DeWine in December 2025. That emergency rule was set to expire June 10, 2026. By proceeding through the JCARR process without invalidation, the rule can now take effect on a permanent basis.

“Synthetic formulations present a clear and immediate risk,” continued Rep. Brennan. “These substances can be significantly more potent than morphine and are often sold in unregulated settings, making them accessible to minors. Allowing this rule to stand helps close that dangerous gap.”

Rep. Brennan also emphasized that broader questions surrounding natural kratom remain under review.

“There are strong and deeply personal perspectives on this issue, reflected in the more than 1,600 public comments submitted on proposals related to natural kratom,” added Rep. Brennan. “It is appropriate that we proceed carefully, take in all the evidence, and fully understand the impact before considering any broader action.”

A separate proposal under consideration by the Board of Pharmacy would impose a broader ban on both synthetic and natural kratom, while legislation pending in the Ohio General Assembly seeks to regulate natural kratom products and prohibit synthetic compounds.

“As policymakers, we have a responsibility to act where the risks are clear while continuing to do our due diligence on more complex issues,” concluded Rep. Brennan. “Today’s action reflects that balance.”